Biomarker Testing Advocacy Gains Momentum in North Carolina: Parents and Doctors Urge Insurance Coverage for Life-Saving Treatments

A growing chorus of North Carolina parents and medical professionals is raising their voices, advocating for legislation that would mandate insurance coverage for biomarker testing. This advanced diagnostic tool, they argue, is not merely a medical procedure but a critical determinant in securing the most effective and life-saving treatments for patients, particularly those battling cancer.

Ashley Fannin, a resident of Clayton and a pediatric oncology nurse, shared a deeply personal account of how biomarker testing proved instrumental in her son Mason’s fight against leukemia. Mason, now a vibrant 14-year-old who enjoys a full life of sports and outdoor activities, was diagnosed with the aggressive form of cancer at the age of six. His journey, Fannin explained, was profoundly shaped by the insights gained from biomarker analysis.

“It helped our doctors decide to increase the frequency of the steroids and chemotherapy from every three months to every month, and we went beyond the standard of care to do an extra year of treatment,” Fannin stated, highlighting the personalized approach enabled by the testing. This tailored strategy, she believes, was crucial in managing her son’s complex diagnosis.

Understanding Biomarker Testing

Biomarkers are specific genetic materials or proteins, identifiable through sophisticated laboratory testing, that can be found in a patient’s tumors or blood. In the realm of oncology, these biomarkers serve as vital clues, enabling physicians to precisely tailor treatment plans to the unique biological profile of an individual’s cancer. However, the high cost of these tests can present a significant barrier, with some insurance plans failing to provide coverage, leaving patients to shoulder the financial burden.

Legislative Push for Coverage

A coalition of influential organizations, including the American Cancer Society Cancer Action Network, the Arthritis Foundation, and the Alzheimer’s Association, is actively championing House Bill 567. This proposed legislation aims to compel insurance providers in North Carolina to extend coverage to biomarker testing.

“In the cancer world, choosing the right treatment plan can mean the difference between a short life expectancy after diagnosis or walking away with a cure,” remarked Rep. Grant Campbell (R-Cabarrus), a medical doctor and a sponsor of the bill. “Biomarkers are intelligence that we can use to save lives and increase cure rates for patients.”

Challenges in the Senate

While the bill received swift approval in the state House last year, it has yet to secure a hearing in the Senate. A significant hurdle emerged when the state Senate previously passed a bill stipulating that any new legislation mandating insurance coverage for specific services must also repeal requirements for an equivalent number of other services. House Bill 567, in its current form, does not meet this specific legislative condition.

Rep. Campbell acknowledged that the bill’s future in the Senate remains uncertain. However, he emphasized that the benefits to patients should not be framed as a “zero-sum game,” suggesting that the imperative to cover life-saving diagnostics should transcend budgetary constraints.

The Impact on Patients

Melissa Horn, director of state legislative affairs at the Arthritis Foundation, underscored the dual benefit of biomarker testing: preventing patients from undergoing ineffective treatments and accelerating access to effective therapies, thereby potentially lowering overall healthcare costs. Dr. Haley Simpson, an oncologist based in Chapel Hill, shared her experiences with patients who were denied coverage for biomarker testing, leading them to receive “generic chemotherapy.”

“Only months later, when their cancer had progressed and they had suffered the side effects of that chemotherapy,” did their insurance eventually approve the testing, Dr. Simpson recounted, illustrating the detrimental delays and suffering caused by the lack of upfront coverage.

National Context and Future Outlook

Currently, 24 states have enacted laws requiring insurance plans to cover biomarker testing, with a few states imposing limitations based on specific insurance types or diseases. Advocates in North Carolina are hopeful that their persistent efforts will lead to similar protections, ensuring that all patients have the opportunity to benefit from the precision and potential of biomarker-driven medical care.